China Traditional Chinese Medicine Holdings Co. Limited reported unaudited consolidated results for the six months ended 30 June 2025. The Group's revenue was approximately RMB7.46 billion, reflecting a decrease of 11.0% compared to RMB8.39 billion for the same period in 2024. The decline in revenue was mainly attributed to a significant increase in the proportion of centralised procurement of concentrated TCM granules and intensified market competition. The revenue of the Group's concentrated TCM granules business segment was approximately RMB2.99 billion, down 14.1% from RMB3.48 billion in the prior-year period, accounting for 40.1% of total revenue. The gross profit margin for the period was 55.6%, compared with 59.1% a year earlier, mainly due to the increased proportion of centralized procurement and a further decline in gross profit margin. During the reporting period, the Group continued to optimize its business structure by focusing on the development of local and advantageous varieties in the Chinese medicinal herbs integration business, while reducing low-margin and high-risk businesses. The TCM great health segment suspended certain product lines and businesses that were homogeneous and lacked market competitiveness. The Group also implemented measures to enhance the safety of the TCM industry chain, strengthen risk management, and improve integrated operations in technology research and development, production, manufacturing, and sales.